-
Je něco špatně v tomto záznamu ?
QSAR Study of N-Myristoyltransferase Inhibitors of Antimalarial Agents
L. Santos-Garcia, MA. de Mecenas Filho, K. Musilek, K. Kuca, TC. Ramalho, EFF. da Cunha,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
NV16-34390A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 1997-01-01
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2009-03-01
Health & Medicine (ProQuest)
od 1997-01-01
- MeSH
- acyltransferasy antagonisté a inhibitory MeSH
- algoritmy MeSH
- antimalarika chemie farmakologie MeSH
- kvantitativní vztahy mezi strukturou a aktivitou MeSH
- léková rezistence účinky léků MeSH
- lidé MeSH
- metoda nejmenších čtverců MeSH
- molekulární modely MeSH
- Plasmodium účinky léků enzymologie MeSH
- protozoální proteiny antagonisté a inhibitory MeSH
- racionální návrh léčiv MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Malaria is a disease caused by protozoan parasites of the genus Plasmodium that affects millions of people worldwide. In recent years there have been parasite resistances to several drugs, including the first-line antimalarial treatment. With the aim of proposing new drugs candidates for the treatment of disease, Quantitative Structure⁻Activity Relationship (QSAR) methodology was applied to 83 N-myristoyltransferase inhibitors, synthesized by Leatherbarrow et al. The QSAR models were developed using 63 compounds, the training set, and externally validated using 20 compounds, the test set. Ten different alignments for the two test sets were tested and the models were generated by the technique that combines genetic algorithms and partial least squares. The best model shows r² = 0.757, q²adjusted = 0.634, R²pred = 0.746, R²m = 0.716, ∆R²m = 0.133, R²p = 0.609, and R²r = 0.110. This work suggested a good correlation with the experimental results and allows the design of new potent N-myristoyltransferase inhibitors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000371
- 003
- CZ-PrNML
- 005
- 20190107104202.0
- 007
- ta
- 008
- 190107s2018 sz f 000 0|eng||
- 024 7_
- $a 10.3390/molecules23092348 $2 doi
- 035 __
- $a (PubMed)30217086
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Santos-Garcia, Letícia $u Departamento de Química, Universidade Federal de Lavras, Lavras 37200-000, Brazil. leticiasantosg@hotmail.com.
- 245 10
- $a QSAR Study of N-Myristoyltransferase Inhibitors of Antimalarial Agents / $c L. Santos-Garcia, MA. de Mecenas Filho, K. Musilek, K. Kuca, TC. Ramalho, EFF. da Cunha,
- 520 9_
- $a Malaria is a disease caused by protozoan parasites of the genus Plasmodium that affects millions of people worldwide. In recent years there have been parasite resistances to several drugs, including the first-line antimalarial treatment. With the aim of proposing new drugs candidates for the treatment of disease, Quantitative Structure⁻Activity Relationship (QSAR) methodology was applied to 83 N-myristoyltransferase inhibitors, synthesized by Leatherbarrow et al. The QSAR models were developed using 63 compounds, the training set, and externally validated using 20 compounds, the test set. Ten different alignments for the two test sets were tested and the models were generated by the technique that combines genetic algorithms and partial least squares. The best model shows r² = 0.757, q²adjusted = 0.634, R²pred = 0.746, R²m = 0.716, ∆R²m = 0.133, R²p = 0.609, and R²r = 0.110. This work suggested a good correlation with the experimental results and allows the design of new potent N-myristoyltransferase inhibitors.
- 650 _2
- $a acyltransferasy $x antagonisté a inhibitory $7 D000217
- 650 _2
- $a algoritmy $7 D000465
- 650 _2
- $a antimalarika $x chemie $x farmakologie $7 D000962
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a léková rezistence $x účinky léků $7 D004351
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metoda nejmenších čtverců $7 D016018
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a Plasmodium $x účinky léků $x enzymologie $7 D010961
- 650 _2
- $a protozoální proteiny $x antagonisté a inhibitory $7 D015800
- 650 _2
- $a kvantitativní vztahy mezi strukturou a aktivitou $7 D021281
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a de Mecenas Filho, Marco Antônio $u Departamento de Química, Universidade Federal de Lavras, Lavras 37200-000, Brazil. marcomecenasfilho@gmail.com.
- 700 1_
- $a Musilek, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove 50005, Czech Republic. kamil.musilek@uhk.cz. Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove 50005, Czech Republic. kamil.musilek@uhk.cz.
- 700 1_
- $a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove 50005, Czech Republic. kamil.kuca@uhk.cz.
- 700 1_
- $a Ramalho, Teodorico Castro $u Departamento de Química, Universidade Federal de Lavras, Lavras 37200-000, Brazil. teo@dqi.ufla.br. Center for Basic and Applied Research, University Hradec Kralove, Hradec Kralove 50005, Czech Republic. teo@dqi.ufla.br.
- 700 1_
- $a da Cunha, Elaine Fontes Ferreira $u Departamento de Química, Universidade Federal de Lavras, Lavras 37200-000, Brazil. elaine_cunha@dqi.ufla.br.
- 773 0_
- $w MED00180394 $t Molecules $x 1420-3049 $g Roč. 23, č. 9 (2018), s.
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30217086 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a
- 990 __
- $a 20190107 $b ABA008
- 999 __
- $a ok $b bmc $g 1364474 $s 1038494
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 23 $c 9 $e 20180913 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- GRA __
- $a NV16-34390A $p MZ0
- LZP __
- $a Pubmed-20190107